Issue Date: July 18, 2016
Celgene, others back start-up Sapience
Sapience Therapeutics has raised $22.5 million in a Series A financing round lead by Eshelman Ventures and including Celgene, TaiAn Technologies, and Healthlink Capital. Sapience is based on ST-36, a peptide-based drug that was licensed from Columbia University. Sapience says ST-36 selectively targets a protein that promotes the growth of many types of tumors. Its initial target is glioblastoma, a brain cancer.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society